Drug Trial Radar · NCT01371825
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
Last checked: Nov 20, 2026Latest source record: Jan 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
May 4, 2011
Primary completion
Jan 3, 2018
Study completion Jan 3, 2018
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 13, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency. Eligible participants received once-weekly (qw) infusions of sebelipase alfa for up to 5 years.
Conditions
- Lysosomal Acid Lipase Deficiency
- Wolman Disease
Interventions
Sebelipase alfa (SBC-102)Drug
Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Of Participants In The Primary Efficacy Analysis Set (PES) Surviving To 12 Months Of AgeTime frame: Month 12
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Irvine, California
Site not named
Cairo, Egypt
Site not named
Grenoble, France
Site not named
Paris, France
Site not named
Dublin, Ireland
Site not named
London, United Kingdom
Site not named
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.